Your browser doesn't support javascript.
loading
Identification of Genomic Signatures for Colorectal Cancer Survival Using Exploratory Data Mining.
Hummel, Justin J; Liu, Danlu; Tallon, Erin; Snyder, John; Warren, Wesley; Shyu, Chi-Ren; Mitchem, Jonathan; Cortese, Rene.
Afiliação
  • Hummel JJ; Institute for Data Science and Informatics, University of Missouri, Columbia, MO 65212, USA.
  • Liu D; Department of Electrical Engineering and Computer Science, University of Missouri, Columbia, MO 65212, USA.
  • Tallon E; Institute for Data Science and Informatics, University of Missouri, Columbia, MO 65212, USA.
  • Snyder J; Department of Statistics, University of Missouri, Columbia, MO 65212, USA.
  • Warren W; Institute for Data Science and Informatics, University of Missouri, Columbia, MO 65212, USA.
  • Shyu CR; Division of Animal Sciences, University of Missouri, Columbia, MO 65212, USA.
  • Mitchem J; Department of Surgery, University of Missouri, Columbia, MO 65212, USA.
  • Cortese R; Institute for Data Science and Informatics, University of Missouri, Columbia, MO 65212, USA.
Int J Mol Sci ; 25(6)2024 Mar 12.
Article em En | MEDLINE | ID: mdl-38542194
ABSTRACT
Clinicopathological presentations are critical for establishing a postoperative treatment regimen in Colorectal Cancer (CRC), although the prognostic value is low in Stage 2 CRC. We implemented a novel exploratory algorithm based on artificial intelligence (explainable artificial intelligence, XAI) that integrates mutational and clinical features to identify genomic signatures by repurposing the FoundationOne Companion Diagnostic (F1CDx) assay. The training data set (n = 378) consisted of subjects with recurrent and non-recurrent Stage 2 or 3 CRC retrieved from TCGA. Genomic signatures were built for identifying subgroups in Stage 2 and 3 CRC patients according to recurrence using genomic parameters and further associations with the clinical presentation. The summarization of the top-performing genomic signatures resulted in a 32-gene genomic signature that could predict tumor recurrence in CRC Stage 2 patients with high precision. The genomic signature was further validated using an independent dataset (n = 149), resulting in high-precision prognosis (AUC 0.952; PPV = 0.974; NPV = 0.923). We anticipate that our genomic signatures and NCCN guidelines will improve recurrence predictions in CRC molecular stratification.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Inteligência Artificial / Neoplasias Colorretais Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Inteligência Artificial / Neoplasias Colorretais Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article